NYSE: SCLStepan Co Stock
$50.56-1.04 (-2.02%)
Updated Apr 30, 2025
SCL Price
$50.56
Fair Value Price
N/A
Market Cap
$1.14B
52 Week Low
$44.23
52 Week High
$94.77
P/E
22.88x
P/B
0.97x
P/S
0.68x
PEG
0.65x
Dividend Yield
2.27%
Revenue
$2.18B
Earnings
$50.37M
Gross Margin
12.5%
Operating Margin
3.42%
Profit Margin
2.3%
Debt to Equity
0.97
Operating Cash Flow
$162M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
May 30, 2025
Next Dividend
Jun 13, 2025
SCL Overview
Stepan Company manufacturers basic and intermediate chemicals, including surfactants, specialty products, phthalic anhydride, and polyurethane polyols. Surfactants are used in cleaning agents and consumer products like detergents, toothpaste, and cosmetics. Surfactants also have commercial and industrial applications ranging from emulsifiers for agricultural insecticides to agents used in oil recovery. The company also makes phthalic anhydride and other polymers for food and pharmaceutical uses. Stepan was founded in 1932 and is headquartered in Northbrook, IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCL's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important SCL news, forecast changes, insider trades & much more!
SCL News
Overview
Due Diligence Score
–
Industry Average (36)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCL scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCL ($50.56) is trading above its intrinsic value of $40.19, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SCL is good value based on its earnings relative to its share price (22.88x), compared to the US market average (29.18x)
P/E vs Market Valuation
SCL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more SCL due diligence checks available for Premium users.
Valuation
SCL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
22.88x
Industry
28.11x
Market
29.18x
SCL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SCL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SCL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.97x
Industry
3.2x
SCL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SCL price to earnings growth (PEG)
For valuing profitable companies with growth potential
SCL is good value based... subscribe to Premium to read more.
PEG Value Valuation
SCL's financial health
Profit margin
Revenue
$525.6M
Net Income
$3.4M
Profit Margin
0.6%
SCL's Earnings (EBIT) of $74.62M... subscribe to Premium to read more.
Interest Coverage Financials
SCL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.3B
Liabilities
$1.1B
Debt to equity
0.97
SCL's short-term assets ($810.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCL's short-term assets ($810.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SCL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$68.3M
Investing
-$36.2M
Financing
-$71.4M
SCL's operating cash flow ($162.05M)... subscribe to Premium to read more.
Debt Coverage Financials
SCL vs Specialty Chemical Stocks
Stepan Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.